We’re joined by Dr. Melinda Elliott, neonatologist and chief medical officer at Prolacta Bioscience, to discuss what leading NICUs are doing today to nurture their tiniest patients.

More than 100,000 extremely premature infants worldwide 17 have benefited from Prolacta's human milk-based products, which have been evaluated in more than 30 peer-reviewed clinical studies.

More than 100,000 extremely premature infants worldwide 2 have benefited from Prolacta's human milk-based products, which have been evaluated in more than 30 peer-reviewed clinical studies.

DUARTE, Calif., July 6, 2023 /PRNewswire/ -- Prolacta Bioscience ®, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants ...

DUARTE, Calif., July 24, 2024 /PRNewswire/ -- Prolacta Bioscience ®, the world's leading hospital provider of 100% human milk-based nutritional products, takes its obligation to the critically ...

DUARTE, Calif., June 27, 2023 /PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, today ...

DUARTE, Calif., Oct. 1, 2024 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill and premature infants ...